查詢結果分析
來源資料
相關文獻
- A Phase Ⅱ Study of Neoadjuvant Interferon Alfa-2B and Concurrent Interferon and Radiotherapy in Primary Untreated Undifferentiated Carcinoma of Nasopharynx
- 鼻咽癌病人放射線黏膜炎之抑制--比較Salcoat與Dexaltin之隨機取樣試驗
- 以逆向被動血液凝集法測定鼻咽癌病人血清中的Υ型干擾素
- 放射治療後長期存活之鼻咽癌病人的生活品質調查
- 鼻咽癌病人在放射治療前後鼓室圖之變化
- 晚期鼻咽癌同步化學放射治療與單獨放射治療臨床結果之比較--隨機分組試驗初步報告
- 不同方式放射線照射法對鼻咽癌病人唾液腺功能之影響
- Radiotherapy Versus Combined Radiotherapy and Chemotherapy for T[feb2]Nasopharyngeal Carcinoma
- 鼻咽癌病患放射治療後聽力之維護
- Elective Neck Irradiation for Nasopharyngeal Carcinoma
頁籤選單縮合
題 名 | A Phase Ⅱ Study of Neoadjuvant Interferon Alfa-2B and Concurrent Interferon and Radiotherapy in Primary Untreated Undifferentiated Carcinoma of Nasopharynx=單用合成干擾素與併用合成干擾素與放射治療對鼻咽癌患者的第二期臨床研究 |
---|---|
作 者 | 林賢岳; 季匡華; 羅志剛; 顏上惠; | 書刊名 | 放射治療與腫瘤學 |
卷 期 | 5:4 1998.12[民87.12] |
頁 次 | 頁261-268 |
分類號 | 416.879、416.879 |
關鍵詞 | 干擾素; 鼻咽癌; 放射治療; Interferon; NPC; Radiotherapy; |
語 文 | 英文(English) |
中文摘要 | 目的:為了同時能評估合成干擾素治療分化不良鼻咽癌患者之療效,我們執行了 一個第二期臨床計劃,將廣犯性鼻咽癌患者先以干擾素治療數週以準備放射治療,再同步進 行放射治療與干擾素注射,觀察干擾素在鼻咽癌治療之角色。材料與方法:共有 14 位患者 進入此研究接受干擾素 300 萬單位,一週三次的皮下注射的治療, 平均治療六週後,初步 評估其療效,而後病患接受每天 180 至 200 cGy 不等的局部放射治療共計 7000cGy。其間 病患仍然接受相同劑量的干擾素皮下注射。結果:共計有 13 位患者得以評估單用干擾素的 療效,無病患可觀察到明顯的腫瘤抑制作用,7 位患者腫瘤反而有繼續增長的趨勢。其中有 12 位患者接受併用干擾素與放射治療的治療,全部患者皆能有明顯而快速的腫瘤縮小,83% 病灶完全消失,然而 100% 的患者有第三度左右的咽喉粘膜炎且需暫時中斷放射治療。 其它 的毒性反應如發燒、疲倦、骨骼酸痛等全身的症狀多屬輕微,能以解熱退燒劑有效的控制。 經過長期的追�j (最長超過 10 年 ),計有六位患者死於遠端轉移,二例患者有局部復發的 現象。中值存活期為 26 個月。結論:單用干擾素在鼻咽癌為一無效的治療方式,然而卻有 明顯的放射增敏作用,雖然存活期與局部控制率並未有突出之處,本研究提供了干擾素增強 放射治療效果的一個臨床佐證,對未來發展併用干擾素與放射治療,我們仍持樂觀的態度。 |
英文摘要 | Purpose:To determine the efficacy of recombinant interferon alfa-2b (Intron A) (rIFN) in the treatment of primary untreated undifferentiated nasopharyngeal carcinoma (NPC) before radiotherapy and to determine the efficacy and feasibility of combined rIFN and radiotherapy concomitantly. Material and Patients: Fourteen patients enrolled in this study. All of them had histologically proved locally advanced NPC. Patients received rIFN subcutaneous injection with dose of 3 × 10 �� U/body, three times a week for a median of 6 weeks. Then rIFN was continued during the following 7 weeks' radiotherapy period with the same dose and schedule. Radiotherapy consisted of 70 Gy of loco-regional irradation with conventional fractionation. Toxicities and response were evaluated. A long follow-up report was performed. Results:There was no observed response from neoadjuvant rIFN treatment in 13 evaluable patients. Twelve of them received scheduled radiotherapy as well as rIFN treatment. All of them had rapid tumor shrinkage, 10 of them (83%) ahd complete response after radiotherapy. The oropharyngeal mucositis (≧ grade 3) toxicity was quite substantial, and most patients had been forced to interrupt to radiotherapy course. There were two patients with locally failure and 6 had distant metastases. The median survival for those 12 patients who received complete course of treatment was 26 months (rang: 20-140 +months) . Discussion:Interferon single agent is not effective in NPC therapy. The combined use of rIFN and radiotherapy has resulted in a higher oropharyngeal mucositis rate from the radiosensitization effect of rIFN, but it does not translate to a higher local control rate nor lower distant failure rate. The benefit of adjunctive use of rIFN is not evident from this small series of study. In viewing of the better tolerance of rIFN than chemotherapy by most patients, the radiosensitization effect of rIFN can be further studied and explored. |
本系統中英文摘要資訊取自各篇刊載內容。